Does TREPROSTINIL Cause Application site vesicles? 12 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Application site vesicles have been filed in association with TREPROSTINIL (TYVASO). This represents 0.0% of all adverse event reports for TREPROSTINIL.
12
Reports of Application site vesicles with TREPROSTINIL
0.0%
of all TREPROSTINIL reports
1
Deaths
12
Hospitalizations
How Dangerous Is Application site vesicles From TREPROSTINIL?
Of the 12 reports, 1 (8.3%) resulted in death, 12 (100.0%) required hospitalization.
Is Application site vesicles Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TREPROSTINIL. However, 12 reports have been filed with the FAERS database.
What Other Side Effects Does TREPROSTINIL Cause?
Dyspnoea (16,348)
Headache (14,051)
Diarrhoea (11,335)
Nausea (10,320)
Cough (8,945)
Fatigue (7,440)
Dizziness (7,405)
Infusion site pain (5,169)
Vomiting (5,097)
Death (4,764)
What Other Drugs Cause Application site vesicles?
INGENOL MEBUTATE (843)
BUPRENORPHINE (700)
SUMATRIPTAN (262)
NICOTINE (241)
MINOXIDIL (188)
ESTRADIOL (179)
FENTANYL (170)
PICATO (139)
DICLOFENAC (115)
CHLORHEXIDINE\ISOPROPYL ALCOHOL (80)
Which TREPROSTINIL Alternatives Have Lower Application site vesicles Risk?
TREPROSTINIL vs TREPROSTINIL DIOLAMINE
TREPROSTINIL vs TRETINOIN
TREPROSTINIL vs TRIAMCINOLONE
TREPROSTINIL vs TRIAMCINOLONE ACETONIDE
TREPROSTINIL vs TRIAMCINOLONE HEXACETONIDE